Company news
Q32 Bio Inc. news in 2022
Q32 Bio Inc.'s news releases, calls and decks from 2022, newest first.
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
November 9, 2022
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
October 26, 2022
Homology Medicines to Participate at Upcoming Conferences
October 5, 2022
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
September 5, 2022
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
August 14, 2022
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
August 10, 2022
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
July 4, 2022
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
June 28, 2022
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
June 12, 2022
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
May 17, 2022
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
May 15, 2022
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
May 1, 2022
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
April 20, 2022
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 22, 2022
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
March 9, 2022
Homology Medicines to Participate in Upcoming Investor Conferences
March 2, 2022
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
February 17, 2022
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting
February 9, 2022